Search

Urinary tuberculosis and the busy urologist!

This article is a very good read for any busy urologist. When in medical school, we were taught that tuberculosis (TB) was rare in the UK and other developed countries. We have come full circle; now there are increasing cases...

Male LUTS: where do we stand?

Patients’ preferences and expectations depend on cultural, geographical, economic and national factors. Data from different countries should be interpreted with caution when applied to the individual patient. Patients rarely seek help for benign prostatic obstruction (BPO) unless urinary retention occurs,...

PIRADS-3 lesions and clinically significant prostate cancer – what are we missing?

The use of pre-biopsy MRI has definitely enhanced our decision making in managing patients with suspected prostate cancer (PCa). There is still uncertainty around the outcomes for patients with PIRADS-3 lesions, with a small but definite risk of missing clinically...

Sepsis – still a dilemma

Thousands of people die each year in the UK and worldwide due to types of sepsis, including urosepsis. Urologists are facing this scenario day in day out, so this is a vital article for every reader. We are all familiar...

The cost of bladder cancer: what can be done?

The rising cost of cancer care is a growing concern for health systems. A 2020 study estimated Europe’s annual cancer-related expenditure at €199 billion, with €109 billion attributed to healthcare costs. Bladder cancer (BC), in particular, imposes a significant financial...